Pfizer teams up with Sinopharm to market 12 new drugs in China — report
13 Apr 2023
License out/in
Pfizer and China-based Sinopharm Group have teamed up to seek approval for 12 new drugs in China through 2025,
Reuters reported Thursday
.
Pfizer agreed to a strategic cooperation agreement with the state-owned Sinopharm on Wednesday, with Sinopharm President Liu Yong saying the agreement will accelerate the delivery of Pfizer’s new drugs to patients, Reuters reported.
The deal builds on Pfizer’s recent partnerships in China, with state-owned Meheco agreeing to import and distribute its Covid-19 antiviral Paxlovid through next November, as well as another 5-year deal with Zhejiang Huahai signed last August to produce and sell Paxlovid too.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.